Navigation Links
Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
Date:11/28/2008

WAYNE, Pa., Nov. 28 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on November 21, 2008, it received a letter from Nasdaq stating that since it had not yet filed its 10-Q for the quarterly period ended September 30, 2008 as of the date of the letter, it was no longer in compliance with the rules for continued listing according to Marketplace Rule 4310(c)(14).

The Nasdaq letter advised that Encorium had 60 calendar days from the date of the letter to submit a plan to regain compliance. Encorium filed its Form 10-Q for the quarterly period ended September 30, 2008 on Wednesday, November 26, 2008 and has notified Nasdaq of its filing. As a result, the Company anticipates it will receive notice from Nasdaq that it is currently in compliance with Nasdaq Marketplace Rule 4310(c)(14).

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health an
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 Bionomics Limited (ASX:BNO, ADR:BMICY) is ... of BNC105 in patients with metastatic renal cancer at ... Florida . The data will be presented by ... Hope Comprehensive Cancer Center in California ... new data identifies Ferritin and IL-8 as two baseline ...
(Date:2/27/2015)... 27, 2015   PureTech , a science and ... disruptive products and technologies in the healthcare sector, announced ... CEO and Member of the Board of Directors of ... "It,s has been a pleasure to know Chris for ... will be working together more closely now," said Dr. ...
(Date:2/26/2015)... 2015   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today reported 2014 ... other key objectives, and financial guidance.  Synageva,s management ... 4:30 p.m. EST to review the financial results ... in today,s call by telephone, please dial (877) ...
(Date:2/26/2015)... On behalf of biotech client GenScript USA, ... & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript’s ... for judgment notwithstanding the verdict, a new trial, and ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... Mich., Oct. 11 Compendia Bioscience, Inc.,today announced ... Track Award from,the National Cancer Institute to support ... Platform for Biopharmaceutical Research and,Development". (Logo: ... Ph.D., who will serve as the principal,investigator for ...
... the prevention and treatment of ... safety and comfort, BATESVILLE, Ind., Oct. 11 ... Hill-Rom subsidiary has,introduced a revolutionary new hospital bed surface ... Hill-Rom(R) E700 Wound Surface (a,low air loss therapy surface) ...
... provides pharmacy staff with the ability to ... manage every pharmaceutical in the hospital, MOUNTAIN VIEW, Calif. ... ), a leading provider,of system solutions to acute healthcare facilities, ... Chambersburg,Hospital has reduced cart-fill time from 16 man-hours to 90 ...
Cached Biology Technology:Compendia Bioscience Announces the Receipt of a $2.4M SBIR Award and Related Management Changes 2Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 2Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 3Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 4Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 5Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0 2Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0 3
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... Princeton engineers have developed a sensor that may revolutionize how ... the process also help ensure the survival of two species ... credit goes to an African frog. In the wild, ... of amino acids -- on its skin to protect it ...
... of Medicine have found that new disease pathways involving ... Gaucher disease, a rare genetic disorder in which fatty ... enlargement, osteoporosis, bone pain, and increased risk of cancer ... lead to less expensive and more effective ways to ...
... COLUMBIA, Mo. If finding the cure for a fungus ... of a detective show, University of Missouri Chemistry Professor John ... high-tech equipment to make a model that could eventually solve ... of Arts and Science, has joined forces with Pablo Sobrado, ...
Cached Biology News:New sensor derived from frogs may help fight bacteria and save wildlife 2New sensor derived from frogs may help fight bacteria and save wildlife 3Cheaper, more effective treatment of type 1 Gaucher disease possible 2X-ray diffraction may play key role in stopping 'kissing bug,' fungus 2
A univariate (peak height or area) quantitative multi-component analysis package....
... H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 (Disulfide ... peptide and 1 ... I-labelled peptide, please see ... ([ 1 2 ...
... is a dramatic breakthrough in accurate, small-volume bulk ... resolution, the micro 1 has unique advantages not ... micro 1 never needs re-calibration as do other ... on an LCD Display , Graphical Row Selection ...
... high-throuput screening of a biological systems phenotype, ... changes in the expression levels of the ... studied, classified and compared to each other, ... a glance. Automatized scanning of the hybridized ...
Biology Products: